This trial will compare a new treatment for glioblastoma to placebo to see if it extends survival.
1 Primary · 6 Secondary · Reporting Duration: Up to 48 months
2 Treatment Groups
1 of 2
1 of 2
93 Total Participants · 2 Treatment Groups
Primary Treatment: IGV-001 Cell Immunotherapy · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 70 · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does the age restriction for this research allow individuals under 35 to participate?
"To be eligible for this trial, individuals must have surpassed the age of consent and yet not exceeded 70 years old." - Anonymous Online Contributor
What is the upper limit on participant enrollment in this experiment?
"This clinical trial is no longer accepting participants; its posting was initially published on December 1st 2022, and the page was last updated June 24th 2022. If you are seeking alternative studies, there are currently 442 trials for glioblastoma patients and 206 related to IGV-001 Cell Immunotherapy that remain open." - Anonymous Online Contributor
Would I be eligible to join this medical investigation?
"To be eligible for this medical trial, patients must have glioblastoma and fall within the age range of 18 to 70. The team is looking to enroll 93 people in total." - Anonymous Online Contributor
To what maladies is IGV-001 Cell Immunotherapy typically applied?
"IGV-001 Cell Immunotherapy is often prescribed to patients undergoing nitrosourea treatment, and can be employed in cases of advanced mycosis fungoides, refractory neuroblastoma, advance directives or treatments with limited efficacy." - Anonymous Online Contributor
What other research efforts have been conducted pertaining to IGV-001 Cell Immunotherapy?
"In 2002, the Memorial Sloan Kettering Cancer Center initiated its research into IGV-001 Cell Immunotherapy. Since then, 18614 clinical trials have been completed with 206 currently active ones concentrated in Philadelphia, Pennsylvania." - Anonymous Online Contributor
What is the breadth of this experiment's geographical distribution?
"At the moment, 34 medical trial sites are running this clinical study across America with Philadelphia, Newark and Boston being among them. To reduce travel time if you participate in the research, it is important to choose a nearby site location." - Anonymous Online Contributor
Is recruitment still taking place for this experiment?
"Contrary to the information hosted on clinicaltrials.gov, this medical trial is not enrolling patients as of now; it was first uploaded on December 1st 2022 and its record most recently updated June 24th 20212. However, there are 648 other trials actively recruiting participants at present." - Anonymous Online Contributor
Is this research novel or has it been conducted elsewhere?
"At present, there are 206 ongoing studies involving IGV-001 Cell Immunotherapy in 935 cities across 36 countries. This experimental drug first underwent clinical trials in 2002 under the auspices of Schering-Plough. Initially testing 60 patients during its Phase 2 approval process, 18614 further trials have been completed since then." - Anonymous Online Contributor
Has IGV-001 Cell Immunotherapy been given the stamp of approval by the FDA?
"This [immunotherapy](https://www.withpower.com/clinical-trials/immunotherapy) is still in the process of being evaluated for safety, so it was given a score of 2 on our rating scale. As this is only Phase 2 trial, there are some data points indicating its safety but no information on efficacy yet." - Anonymous Online Contributor